Investigational drug · Phase 3
AD-224B
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension,Essential.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "AD-224B"
First trial start
2024
Apr 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-224B", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension,Essential
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-224B" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of AD-224Pivotal-lookingCompleted
Addpharma Inc.Industry
NCT06291207 · 254 participants · Start Apr 15, 2024 · Primary completion Apr 7, 2025
Drug: AD-224A; AD-224B and 4 more · For: Hypertension,Essential
Sites: Seongnam-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension,Essential
- AD-223APhase 31 trial
Addpharma Inc. · Hypertension,Essential
- AD-223BPhase 31 trial
Addpharma Inc. · Hypertension,Essential
- AD-223CPhase 31 trial
Addpharma Inc. · Hypertension,Essential
- AD-224APhase 31 trial
Addpharma Inc. · Hypertension,Essential
- AD-224CPhase 31 trial
Addpharma Inc. · Hypertension,Essential
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.